TriangleNCT02420795 · OUTCOME
Number of Participants With Overall Response Rate (Phase 1 and 2)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- Up to 63 days (first 3 courses)
What was measured
Defined as either progressive disease or stable disease observed assessed by the Revised International Workshop Standardization Response Criteria for non-Hodgkin lymphoma.
Analysis population: 1 patient passed away prior to restaging in Phase 2 Arm B
Groups in this outcome
ONC201 125 mg
Patients receive Akt/ERK inhibitor ONC201 125 mg PO on day 1 of every cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
ONC201 250 mg
Patients receive Akt/ERK inhibitor ONC201 250 mg PO every 7 days. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
ONC201 625 mg
Patients receive Akt/ERK inhibitor ONC201 625 mg PO every 7 days. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
| Group | Source count |
|---|---|
| ONC201 125 mg | 4 |
| ONC201 250 mg | 2 |
| ONC201 625 mg | 5 |
Reported measurements
Progressive Disease
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| ONC201 125 mg | 3 | Not reported | Not reported | Not reported | Not reported |
| ONC201 250 mg | 1 | Not reported | Not reported | Not reported | Not reported |
| ONC201 625 mg | 3 | Not reported | Not reported | Not reported | Not reported |
Stable Disease
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| ONC201 125 mg | 1 | Not reported | Not reported | Not reported | Not reported |
| ONC201 250 mg | 1 | Not reported | Not reported | Not reported | Not reported |
| ONC201 625 mg | 1 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 3
- title
- Progressive Disease
- categories
- measurements
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 1
- title
- Stable Disease
- denoms
- counts
- group Id
- OG000
- value
- 4
- group Id
- OG001
- value
- 2
- group Id
- OG002
- value
- 5
- units
- Participants
- description
- Defined as either progressive disease or stable disease observed assessed by the Revised International Workshop Standardization Response Criteria for non-Hodgkin lymphoma.
- groups
- description
- Patients receive Akt/ERK inhibitor ONC201 125 mg PO on day 1 of every cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
- id
- OG000
- title
- ONC201 125 mg
- description
- Patients receive Akt/ERK inhibitor ONC201 250 mg PO every 7 days. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
- id
- OG001
- title
- ONC201 250 mg
- description
- Patients receive Akt/ERK inhibitor ONC201 625 mg PO every 7 days. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
- id
- OG002
- title
- ONC201 625 mg
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- 1 patient passed away prior to restaging in Phase 2 Arm B
- reporting Status
- POSTED
- time Frame
- Up to 63 days (first 3 courses)
- title
- Number of Participants With Overall Response Rate (Phase 1 and 2)
- type
- PRIMARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice